Enjoy these CME sessions at AAO 2023
Register Now!
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
Register Now!
The Ophthalmology Times EyeCon 2023
Register Now!
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
(CME/CNE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
Novartis finalizes divestment of ‘front of eye’ ophthalmology assets
According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.
Outlook Therapeutics requests Type A meeting with FDA
According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.